View Item 

Show simple item record

Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorZhao, Carol
dc.contributor.authorSaggar, Rajan
dc.contributor.authorMathai, Stephen C.
dc.contributor.authorChung, Lorinda
dc.contributor.authorCoghlan, J. Gerry
dc.contributor.authorShah, Mehul
dc.contributor.authorHartney, John
dc.contributor.authorMcLaughlin, Vallerie
dc.date.accessioned2021-05-12T17:24:18Z
dc.date.available2022-06-12 13:24:17en
dc.date.available2021-05-12T17:24:18Z
dc.date.issued2021-05
dc.identifier.citationKhanna, Dinesh; Zhao, Carol; Saggar, Rajan; Mathai, Stephen C.; Chung, Lorinda; Coghlan, J. Gerry; Shah, Mehul; Hartney, John; McLaughlin, Vallerie (2021). "Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries." Arthritis & Rheumatology (5): 837-847.
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/2027.42/167481
dc.publisherWiley Periodicals, Inc.
dc.titleLong‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167481/1/art41669_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167481/2/art41669.pdf
dc.identifier.doi10.1002/art.41669
dc.identifier.sourceArthritis & Rheumatology
dc.identifier.citedreferenceKolstad KD, Li S, Steen V, Chung L, on behalf of the PHAROS Investigators. Long‐term outcomes in systemic sclerosis‐associated pulmonary arterial hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest 2018; 154: 862 – 71.
dc.identifier.citedreferenceYaylalı YT, Başarıcı I, Avcı BK, Meriç M, Sinan UY, Şenol H, et al. Risk assessment and survival of patients with pulmonary hypertension: multicenter experience in Turkey. Anatol J Cardiol 2019; 21: 322 – 30.
dc.identifier.citedreferenceZhang R, Dai LZ, Xie WP, Yu ZX, Wu BX, Pan L, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 2011; 140: 301 – 9.
dc.identifier.citedreferenceKeogh A, Strange G, McNeil K, Williams TJ, Gabbay E, Proudman S, et al. The Bosentan Patient Registry: long‐term survival in pulmonary arterial hypertension. Intern Med J 2011; 41: 227 – 34.
dc.identifier.citedreferenceChung WJ, Park YB, Jeon CH, Jung JW, Ko KP, Choi SJ, et al. Baseline characteristics of the Korean registry of pulmonary arterial hypertension. J Korean Med Sci 2015; 30: 1429 – 38.
dc.identifier.citedreferenceCondliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease‐associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151 – 7.
dc.identifier.citedreferenceQian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z, et al. Long‐term prognosis of patients with systemic lupus erythematosus‐associated pulmonary arterial hypertension: CSTAR‐PAH cohort study. Eur Respir J 2019; 53: 1800081.
dc.identifier.citedreferenceKang KY, Jeon CH, Choi SJ, Yoon BY, Choi CB, Lee CH, et al. Survival and prognostic factors in patients with connective tissue disease‐associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry. Int J Rheum Dis 2017; 20: 1227 – 36.
dc.identifier.citedreferenceHao YJ, Jiang X, Zhou W, Wang Y, Gao L, Wang Y, et al. Connective tissue disease‐associated pulmonary arterial hypertension in Chinese patients. Eur Respir J 2014; 44: 963 – 72.
dc.identifier.citedreferenceNgian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, et al. Predictors of mortality in connective tissue disease‐associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012; 14: R213.
dc.identifier.citedreferenceLaunay D, Humbert M, Berezne A, Cottin V, Allanore Y, Couderc LJ, et al. Clinical characteristics and survival in systemic sclerosis‐related pulmonary hypertension associated with interstitial lung disease. Chest 2011; 140: 1016 – 24.
dc.identifier.citedreferenceHachulla E, Jais X, Cinquetti G, Clerson P, Rottat L, Launay D, et al. Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the French pulmonary hypertension registry. Chest 2018; 153: 143 – 51.
dc.identifier.citedreferenceMorrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian GS, et al. Survival and quality of life in incident systemic sclerosis‐related pulmonary arterial hypertension. Arthritis Res Ther 2017; 19: 122.
dc.identifier.citedreferenceWeatherald J, Boucly A, Launay D, Cottin V, Prévot G, Bourlier D, ​et al. Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. Eur Respir J 2018;​ 52:​ 1800678.
dc.identifier.citedreferenceKuwana M, Watanabe H, Matsuoka N, Sugiyama N. Pulmonary arterial hypertension associated with connective tissue disease: meta‐analysis of clinical trials. BMJ Open 2013; 3: e003113.
dc.identifier.citedreferenceAvouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta‐analysis of randomised controlled trials. Ann Rheum Dis 2008; 67: 808 – 14.
dc.identifier.citedreferenceWeatherald J, Montani D, Jevnikar M, Jaïs X, Savale L, Humbert M. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2019; 28: 190023.
dc.identifier.citedreferenceNHS Digital. National audit of pulmonary hypertension: Great Britain, 2018‐19. October 24, 2019. URL: https://files.digit​al.nhs.uk/BA/​4EF20​E/NAPH%2010​A​R%20‐%20Mai​n%20Rep​ort.pdf.
dc.identifier.citedreferenceSobanski V, Giovannelli J, Lynch BM, Schreiber BE, Nihtyanova SI, Harvey J, et al. Characteristics and survival of anti–U1 RNP antibody–positive patients with connective tissue disease–associated pulmonary arterial hypertension. Arthritis Rheumatol 2016; 68: 484 – 93.
dc.identifier.citedreferenceGaliè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53: 1801889.
dc.identifier.citedreferenceLewis RA, Thompson AA, Billings CG, Charalampopoulos A, Elliot CA, Hamilton N, et al. Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J 2020; 55: 2000041.
dc.identifier.citedreferencePeacock AJ, Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, et al. Idiopathic pulmonary arterial hypertension and co‐existing lung disease: is this a new phenotype? Pulm Circ 2020; 10:​ 2045894020914851.
dc.identifier.citedreferenceNagaraja V, Cerinic MM, Furst DE, Kuwana M, Allanore Y, Denton CP, et al. Current and future outlook on disease modification and defining low disease activity in systemic sclerosis. Arthritis Rheumatol 2020; 72: 1049 – 58.
dc.identifier.citedreferenceGaliè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67 – 119.
dc.identifier.citedreferenceD’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343 – 9.
dc.identifier.citedreferenceSimonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34 – 41.
dc.identifier.citedreferenceHumbert M, Sitbon O, Yaïci A, Montani D, O’Callaghan DS, Jaïs X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549 – 55.
dc.identifier.citedreferenceHoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50: 1700740.
dc.identifier.citedreferenceChung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease‐associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138:​ 1383 – 94.
dc.identifier.citedreferenceYoung A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, et al. Update of screening and diagnostic modalities for connective tissue disease‐associated pulmonary arterial hypertension. Semin Arthritis Rheum 2019; 48: 1059 – 67.
dc.identifier.citedreferenceHumbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long‐term survival. Arthritis Rheum 2011; 63: 3522 – 30.
dc.identifier.citedreferenceGaliè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148 – 57.
dc.identifier.citedreferenceGaliè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894 – 903.
dc.identifier.citedreferenceGhofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330 – 40.
dc.identifier.citedreferenceGaliè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834 – 44.
dc.identifier.citedreferenceMcLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46:​ 405 – 13.
dc.identifier.citedreferencePulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809 – 18.
dc.identifier.citedreferenceSitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522 – 33.
dc.identifier.citedreferenceWhite RJ, Jerjes‐Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension: a double‐blind placebo‐controlled clinical trial. Am J Respir Crit Care Med 2020; 201: 707 – 17.
dc.identifier.citedreferenceRhee RL, Gabler NB, Sangani S, Praestgaard A, Merkel PA, Kawut SM. Comparison of treatment response in idiopathic and connective tissue disease‐associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192: 1111 – 7.
dc.identifier.citedreferencePan J, Lei L, Zhao C. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta‐analysis. Clin Exp Rheumatol 2018; 36: 1095 – 102.
dc.identifier.citedreferenceMoher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006 – 12.
dc.identifier.citedreferenceNational Institute for Health Research. PROSPERO: international prospective register of systematic reviews. URL: https://www.crd.york.ac.uk/prosp​ero/.
dc.identifier.citedreferenceSimonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53:​ 1801913.
dc.identifier.citedreferenceDerSimonian R, Laird N. Meta‐analysis in clinical trials. Control Clin Trials 1986; 7: 177 – 88.
dc.identifier.citedreferenceCoghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease‐associated pulmonary arterial hypertension (CTD‐PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2017; 76: 1219 – 27.
dc.identifier.citedreferenceGaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, et al. Selexipag for the treatment of connective tissue disease‐associated pulmonary arterial hypertension. Eur Respir J 2017; 50: 1602493.
dc.identifier.citedreferenceRubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896 – 903.
dc.identifier.citedreferenceDenton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open‐label extensions. Ann Rheum Dis 2006; 65: 1336 – 40.
dc.identifier.citedreferenceBadesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007; 34: 2417 – 22.
dc.identifier.citedreferenceGaliè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double‐blind, placebo‐controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010 – 9.
dc.identifier.citedreferenceBadesch DB. Ambrisentan therapy for pulmonary arterial hypertension: a comparison by PAH etiology [abstract]. Chest 2007; 132 Suppl: 488b – 9.
dc.identifier.citedreferenceGaliè N, Denton CP, Dardi F, Manes A, Mazzanti G, Li B, et al. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. Int J Cardiol 2017; 235: 67 – 72.
dc.identifier.citedreferenceEscribano‐Subias P, Blanco I, López‐Meseguer M, Lopez‐Guarch CJ, Roman A, Morales P, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 2012; 40: 596 – 603.
dc.identifier.citedreferenceMcLaughlin VV, Langer A, Tan M, Clements PJ, Oudiz RJ, Tapson VF, et al. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. Chest 2013; 143: 324 – 32.
dc.identifier.citedreferenceBenza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long‐term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448 – 56.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art41669_am.pdf
Size:
340.8KB
Format:
PDF
View/Open
Name:
art41669.pdf
Size:
296.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.